Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Accumulated Expenses: 2017-2024

Historic Accumulated Expenses for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $13.3 million.

  • Cidara Therapeutics' Accumulated Expenses rose 732.64% to $71.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.3 million, marking a year-over-year increase of 732.64%. This contributed to the annual value of $13.3 million for FY2024, which is 5.85% down from last year.
  • As of FY2024, Cidara Therapeutics' Accumulated Expenses stood at $13.3 million, which was down 5.85% from $14.2 million recorded in FY2023.
  • Cidara Therapeutics' Accumulated Expenses' 5-year high stood at $14.2 million during FY2023, with a 5-year trough of $7.7 million in FY2022.
  • For the 3-year period, Cidara Therapeutics' Accumulated Expenses averaged around $11.7 million, with its median value being $13.3 million (2024).
  • In the last 5 years, Cidara Therapeutics' Accumulated Expenses surged by 95.65% in 2020 and then dropped by 24.77% in 2022.
  • Over the past 5 years, Cidara Therapeutics' Accumulated Expenses (Yearly) stood at $8.0 million in 2020, then rose by 28.13% to $10.2 million in 2021, then declined by 24.77% to $7.7 million in 2022, then skyrocketed by 84.79% to $14.2 million in 2023, then dropped by 5.85% to $13.3 million in 2024.